Harnessing Stem Cell-Derived Extracellular Vesicles for the Regeneration of Degenerative Bone Conditions
Zhiwei Jia,Shunxin Zhang,Wei Li
DOI: https://doi.org/10.2147/ijn.s424731
IF: 7.033
2023-09-30
International Journal of Nanomedicine
Abstract:Zhiwei Jia, 1 Shunxin Zhang, 2 Wei Li 3 1 Department of Orthopedics, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 101100, People's Republic of China; 2 Department of Ultrasound, 2nd Medical Center of PLA General Hospital, Beijing, 100853, People's Republic of China; 3 Department of Sports Medicine, Fourth Medical Center of PLA General Hospital, Beijing, 100048, People's Republic of China Correspondence: Wei Li, Department of Sports Medicine, Fourth Medical Center of PLA General Hospital, Beijing, 100048, People's Republic of China, Email Shunxin Zhang, Department of Ultrasound, 2nd Medical Center of PLA General Hospital, Beijing, 100853, People's Republic of China, Email Degenerative bone disorders such as intervertebral disc degeneration (IVDD), osteoarthritis (OA), and osteoporosis (OP) pose significant health challenges for aging populations and lack effective treatment options. The field of regenerative medicine holds promise in addressing these disorders, with a focus on utilizing extracellular vesicles (EVs) derived from stem cells as an innovative therapeutic approach. EVs have shown great potential in stimulating biological responses, making them an attractive candidate for rejuvenating degenerative bone disorders. However, a comprehensive review summarizing the current state of this field and providing a clear assessment of EV-based therapies in degenerative bone disorders is currently deficient. In this review, we aim to fill the existing gap by outlining the current knowledge on the role of EVs derived from different types of stem cells, such as mesenchymal stem cells, embryonic stem cells, and induced pluripotent stem cells, in bone regeneration. Furthermore, we discuss the therapeutic potential of EV-based treatments for IVDD, OA, and OP. By substantiating the use of stem cell-derived EVs, we highlight their promising potential as a cell-free strategy to improve degenerative bone disorders. Keywords: nanomedicine, extracellular vesicles, stem cells, regeneration, therapy Degenerative bone disorders, encompassing conditions such as intervertebral disc degeneration (IVDD), osteoarthritis (OA), and osteoporosis (OP), exert a profound impact on the well-being of individuals. These disorders pose a substantial healthcare burden, particularly within aging populations. 1 These insidious conditions are characterized with the relentless decay of bone and cartilage, causing excruciating pain, debilitating loss of function, and a significant reduction in mobility. 2–4 Unfortunately, the available treatment options for degenerative bone disorders remain frustratingly limited, often falling short of delivering long-term relief and restoration. The current medical context underscores the imperative to promptly attend to these unmet medical requirements, inciting an increasing enthusiasm for the investigation of novel therapeutic strategies. In recent years, the landscape of regenerative medicine has been transformed by the emergence of stem cell-derived extracellular vesicles (EVs) therapies, presenting a promising approach for improving degenerative bone disorders. These diminutive yet potent membrane-enclosed vesicles, released by stem cells, have emerged as the effective factors responsible for the regenerative outcomes witnessed in stem cell therapies. With their bioactive cargo, these EVs derived from stem cells release a complex of regenerative signals, directing a coordinated interaction within the complicated microenvironment of deteriorating bone. This captivating phenomenon has captured the attention of both researchers and clinicians, as stem cell-derived EVs show their remarkable potential in reshaping the landscape of regenerative medicine. 5 These EVs contain a diverse cargo of bioactive molecules, including proteins, lipids, and RNAs, which can be transferred to recipient cells. Through this transfer, stem cell-derived EVs participate in crucial molecular signaling, influencing cellular behavior and initiating regenerative processes within target tissues. 6 For instance, Rong et al made a significant discovery when they conducted a study that shed light on the remarkable capabilities of neural stem cell-derived EVs. Their research revealed that these tiny vesicles, released by neural stem cells, played a pivotal role in the upregulation of autophagy marker proteins LC3B and beclin-1. As a result, a cascade of events unfolded, leading to the enhancement of autophagosome formation, which in turn contributed to the promotion of functional recovery in individuals with spinal cord injuries. 7 By harnessing the inherent regenerative attributes of stem cells and utilizing the distinctive cargo encapsulated within their secreted EVs, researchers and clinician -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology